Exciting news! STAT has moved its comment section to our subscriber-only app, STAT+ Connect. Subscribe to STAT+ today to join the conversation or join us on Twitter, Facebook, LinkedIn, and Threads. Let’s stay connected!
To submit a correction request, please visit our Contact Us page.
EQS-News: ActiTrexx GmbH / Key word(s): Study ActiTrexx treats first patient with novel regulatory T cell therapy against Graft-versus-Host Disease 19.03.2024 / 10:00 CET/CEST The
Eben Scanlon, Chief Customer Officer at OneStudyTeam Patient engagement is critical on several levels. It helps inform updates to trial design and processes, it ensures
What happened to the House vote on health care price transparency?
Exciting news! STAT has moved its comment section to our subscriber-only app, STAT+ Connect. Subscribe to STAT+ today to join the conversation or join us on Twitter, Facebook, LinkedIn, and Threads. Let’s stay connected!
To submit a correction request, please visit our Contact Us page.
Samsung Bio and Baxter dial up manufacturing deal to $223M
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
ActiTrexx treats first patient with novel regulatory T cell therapy against Graft-versus-Host Disease – Biotech Investments
EQS-News: ActiTrexx GmbH / Key word(s): Study ActiTrexx treats first patient with novel regulatory T cell therapy against Graft-versus-Host Disease 19.03.2024 / 10:00 CET/CEST The
5 Ways Tech is Enhancing Patient Engagement in Clinical Trials
Eben Scanlon, Chief Customer Officer at OneStudyTeam Patient engagement is critical on several levels. It helps inform updates to trial design and processes, it ensures